The ACP6 Knouckout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from human Jurkat T lymphocytes, featuring targeted disruption of the ACP6 gene. This loss-of-function model enables investigation of ACP6-dependent regulation of lysophosphatidic acid (LPA) signaling. The polyclonal format provides a heterogeneous pool of edited cells for bulk population studies. The use of CRISPR/Cas9 genome editing ensures efficient gene disruption for functional genomics research.
The Jurkat cell line, established from an acute T cell leukemia, is an immortalized human T lymphocyte model extensively used to study T cell receptor signaling, apoptosis, and HIV infection. These cells express CD3, CD4, and the TCR complex, and activate MAPK/ERK and PI3K/AKT pathways upon stimulation. Jurkat provides a physiologically relevant context for examining genes involved in immune cell function and lipid-mediated signaling.
ACP6 encodes a lysophosphatidic acid phosphatase that hydrolyzes LPA to monoacylglycerol, reducing extracellular and intracellular LPA levels. LPA acts through six G protein-coupled receptors (LPAR1?C6), coupled to heterotrimeric G proteins, activating phospholipase C, protein kinase C, ERK1/2, AKT, and Rho GTPases (RhoA, Rac1). ACP6 negatively regulates LPA-mediated signaling; its loss elevates LPA, enhancing proliferation, migration, and survival pathways. The network includes MAPK/ERK, PI3K/AKT, and Rho GTPase cascades, linking lipid metabolism to cellular responses.
In Jurkat T lymphocytes, ACP6 knockout likely amplifies LPA receptor-driven signaling, modulating T cell activation thresholds, migration, and apoptosis. Enhanced ERK1/2 and AKT activity may alter proliferation, while RhoA/Rac1 activation influences actin cytoskeleton rearrangements for motility and immune synapse formation. Given the role of LPA in immune cell trafficking and inflammation, this model dissects how lipid phosphatases shape T cell functional outcomes. Combined with quantitative LPA measurement and signaling readouts, it provides a powerful system to study ACP6-dependent regulation in immune contexts.
Researchers can use this model to quantify LPA levels via mass spectrometry, monitor signaling by phospho-ERK and phospho-AKT Western blotting, and assess proliferation, migration, and apoptosis. Applications include drug screening for LPA pathway inhibitors, investigation of lipid phosphatase roles in mitochondrial metabolism and T cell biology, and RT-qPCR profiling of LPA receptor expression. This tool supports research in cancer, fibrosis, neuroinflammation, and cardiovascular disease. For further information, contact Ascent Research.
